MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03349ntm a2200349 i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MY-KuUP |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20260420144103.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
t||||fr|||| 000 0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
ta |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
260420t20252025my a|||fr|||| 000 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
THE0010477 (Local) |
| Qualifying information |
Hardback |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
UMPSA |
| Language of cataloging |
eng |
| Transcribing agency |
UMPSA |
| Description conventions |
rda |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
FIST .Y44 2025 r Bc. |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Heg, Yee Wern, |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Synthesis of pyrazoline based compound and computational docking simulation for potential treatment of congestive heart failure / |
| Statement of responsibility, etc. |
Heg Yee Wern |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Kuantan, Pahang : |
| Name of producer, publisher, distributor, manufacturer |
UMPSA, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2025 |
| 264 ## - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
© 2025 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xvi, 80 pages : |
| Other physical details |
illustrations ; |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| Source |
rda |
| File type |
text file |
| Encoding format |
PDF |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Faculty of Industrial Sciences and Technology |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Final Year Report (Bachelor of Applied Science of Industrial Chemistry) -- Universiti Malaysia Pahang Al-Sultan Abdullah - 2025 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Include bibliographical reference |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
The study aimed to synthesize a new pyrazoline-based compound and evaluate its potential as a therapeutic agent for congestive heart failure. In the first phase, the pyrazoline-based compound was synthesized via Aldol condensation and Michael addition reaction. The final structure of the synthesized compound was characterized by using spectroscopic techniques. FTIR analysis revealed disappearing key functional group signal including α,β-unsaturated ketone C=O at 1678.40 cm-1 , confirming Aldol condensation was successful. H 1 and C13 NMR further supported the structure with a singlet at 6.32 ppm for N-H proton and multiplet at 7.20-7.40 ppm for aromatic protons. In C13 NMR, the N-C carbon appeared at 131.35 ppm and 134.5 ppm , while aromatic carbons were observed in the range of 129.60-131.24 ppm. Furthermore, in the second phase, the synthesized compound was subjected to in silico molecular docking study targeting four key cardiovascular enzymes—MAPK14, MMP9, NFKBIA and PTGS2. This study is aimed to analyze protein-ligand interactions and evaluate the compound’s potential as a therapeutic agent for heart failure. The result revealed that the synthesized pyrazoline-based compound exhibit higher binding affinities (-6.648 kcal/mol, -6.453 kcal/mol, -5.929 kcal/mol and -7.083 kcal/mol ) compared to captopril (-4.268 kcal/mol, -4.839 kcal/mol, -4.160 kcal/mol and -4.874 kcal/mol ), though the binding affinity is slightly lower than co-crystal standard (-7.611 kcal/mol, -7.138 kcal/mol, -5.235 kcal/mol and -5.780 kcal/mol ). These findings highlighted the potential of the synthesized compound for further development and the potential of PTGS2 protein to be a more pronounce target protein for synthesized pyrazoline-based compound. The interaction was mediated primarily by hydrogen bonding with the essential amino acid residue LUE145, PHE142 and TRP139 and stacking interaction with PHE142 Finally, the preliminary findings indicated that the newly synthesized pyrazoline-bas |
| 610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Faculty of Industrial Sciences and Technology |
| General subdivision |
Dissertations |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Universities and colleges |
| General subdivision |
Dissertations |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Theses |
| General subdivision |
Dissertations |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
https://umpir.ump.edu.my/id/eprint/46104 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Final Year Report |